8-K: Healthcare Triangle Secures Up to $15M in Convertible Note Financing

Healthcare Triangle, Inc. has entered into an agreement to issue up to $15 million in senior unsecured convertible promissory notes, with an initial tranche of $7.5 million principal amount funded at a 20% original issue discount.

Summary

• Healthcare Triangle, Inc. (HCTI) entered into a Securities Purchase Agreement on November 20, 2025, to issue senior unsecured convertible promissory notes (Notes) for an aggregate original principal amount of up to $15,000,000.
• The initial tranche, with an original principal amount of $7,500,000, was sold for a purchase price of $6,000,000, reflecting a 20% original issue discount (OID).
• The Notes mature on November 20, 2026, and rank senior to all future indebtedness of the Company, and pari passu with other Notes issued under the Purchase Agreement.
• Notes are convertible at the holder's election into common stock at a conversion price that is the greater of 80% of the lowest closing price during the five trading days prior to conversion or a floor price of $0.38 per share.
• The Company must deliver conversion shares within one trading day of a conversion notice; failure to do so incurs liquidated damages of 2% of the outstanding principal amount per month.
• A Registration Rights Agreement (RRA) requires the Company to file a registration statement covering the resale of at least 300% of the maximum number of conversion shares issuable at the floor price, with deadlines and liquidated damages (2% per month, up to 20%) for non-compliance.
• The Company must use commercially reasonable efforts to obtain stockholder approval for the issuance of shares exceeding 19.99% of outstanding common stock, as per Nasdaq Listing Rules.
• Gross proceeds from the initial tranche were $6,000,000, before deducting placement agent fees and other offering expenses.
• RBW Capital Partners LLC acted as placement agent, receiving an 8.0% cash fee of gross proceeds plus $100,000 for legal fees and expenses.

Sentiment

Score: 4

Explanation: While securing capital is a positive for the company's operations and liabilities, the terms of the financing (20% OID, high default interest, significant liquidated damages, and restrictive covenants like 'Most Favored Nations') indicate a high cost of capital and substantial concessions to investors, suggesting potential financial strain or limited financing options. This creates a mixed outlook, leaning slightly negative due to the unfavorable terms.

Positives

• Secured up to $15,000,000 in financing, with an initial $6,000,000 in gross proceeds, providing capital for general working capital and debt repayment.
• The Notes rank senior to all future indebtedness of the Company, offering a degree of protection to the noteholders.
• The convertible nature of the notes provides investors with potential equity upside while maintaining a debt instrument's characteristics.

Negatives

• The initial tranche was issued with a significant 20% original issue discount, meaning the Company received $6,000,000 for a $7,500,000 principal amount.
• High default interest rate of 18% per annum on unpaid amounts and outstanding principal following an Event of Default.
• Substantial liquidated damages of 2% of the outstanding principal per month for failure to timely deliver conversion shares.
• Liquidated damages of 2% per month (up to 20% total) for failing to meet registration statement filing and effectiveness deadlines.
• Placement agent fees are considerable, totaling 8.0% of gross proceeds plus $100,000 for legal fees.
• The 'Most Favored Nations' clause grants investors the right to exchange their securities for more favorable terms in future financings, potentially limiting the Company's flexibility.
• Prohibition on Variable Rate Transactions without the consent of a majority of noteholders, restricting certain future financing options.

Risks

• Failure to obtain stockholder approval for the issuance of shares exceeding the Nasdaq 19.99% cap could result in the Company being required to repay the remaining outstanding balance of the Notes in cash.
• The Company faces significant liquidated damages if it fails to timely deliver conversion shares or meet registration statement deadlines, which could further strain its financial resources.
• Dilution risk for existing shareholders upon conversion of the Notes, especially if the conversion price is reduced due to dilutive issuances or other adjustments.
• The Company's stock becoming a 'penny stock' could trigger a mandatory cash payment to investors, potentially impacting liquidity.
• Any Material Adverse Effect on the Company's business, properties, assets, operations, results of operations, or financial condition could trigger an Event of Default and accelerate repayment obligations.
• The Company must maintain sufficient authorized common stock (150% of shares necessary for full conversion at the Floor Price) to avoid an Event of Default.

Future Outlook

The Company may request investors to purchase up to an additional $15,000,000 in Notes after the second tranche, subject to investor approval and satisfaction of certain conditions. Proceeds from the Notes will be used for general working capital and to repay certain liabilities. The Company is committed to obtaining stockholder approval for share issuances exceeding Nasdaq limits and fulfilling its registration obligations for the resale of conversion shares.

Industry Context

This convertible note financing provides Healthcare Triangle, Inc., a publicly traded company, with crucial capital. Convertible notes are a common financing tool for companies, particularly in growth or transitional phases, allowing them to raise funds without immediate equity dilution while offering investors a blend of debt security and equity upside. The terms, including a significant original issue discount and high default interest, suggest that the company may be accessing capital under less favorable market conditions or has a higher perceived risk profile compared to companies with stronger balance sheets or more traditional financing options.

Comparison to Industry Standards

• The 20% Original Issue Discount (OID) on the initial tranche is relatively high, indicating a significant cost of capital for Healthcare Triangle, Inc. compared to more established companies that typically secure debt with lower OIDs or interest rates.
• The 18% per annum default interest rate is substantially higher than typical corporate debt rates, reflecting a higher risk premium demanded by investors for this type of financing.
• The 'Most Favored Nations' clause and robust anti-dilution provisions are common in private placements with institutional investors, especially for companies where future capital raises are anticipated, aiming to protect early investors from subsequent, potentially more favorable, financing terms.
• The requirement for stockholder approval for share issuances exceeding 19.99% of outstanding common stock is a standard compliance measure under Nasdaq Listing Rule 5635(d), ensuring shareholder protection against excessive dilution without their consent.

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential significant dilution upon conversion of the Notes, especially given the conversion price mechanisms and the possibility of future dilutive issuances. The 20% OID and high fees effectively reduce the net capital received by the company per share equivalent, impacting shareholder value.
• Investors (Note Holders): Benefit from a senior unsecured debt instrument with equity upside potential, strong anti-dilution protections, high default interest rates, and 'Most Favored Nations' clauses, providing favorable terms and downside protection.
• Company: Gains access to capital for working capital and debt repayment, which is critical for operations, but at a high cost and with restrictive covenants that could limit future financing flexibility and increase financial risk if obligations are not met.

Next Steps

• The Company will file a registration statement covering the resale of conversion shares as required by the Registration Rights Agreement.
• The Company will seek stockholder approval for the issuance of shares exceeding Nasdaq's 19.99% cap by November 28, 2025.
• The Company may request the investors to purchase additional tranches of Notes, up to $15,000,000, after the satisfaction of certain conditions.
• Proceeds from the Notes will be used for general working capital and to repay certain liabilities.

Key Dates

Keywords

Convertible Notes, Securities Purchase Agreement, Healthcare Triangle, HCTI, Financing, Debt, Equity, Original Issue Discount, Registration Rights, Nasdaq Listing Rules, Dilution, Institutional Investors